Imprimis Pharmaceuticals

Imprimis releases low-cost Daraprim alternative

Monday, October 26, 2015

Imprimis Pharmaceuticals, a specialty pharmaceutical company focused on the development and commercialization of proprietary compounded drug therapies, has made a customizable, compounded formulation of pyrimethamine and leucovorin available for physicians to consider prescribing for their patients as a low-cost alternative to Daraprim.

[Read More]

Imprimis acquires intellectual property from Novel Drug Solutions, Eye Care Northwest

Wednesday, August 28, 2013

Imprimis Pharmaceuticals, focused on the commercialization of drug formulations through a growing proprietary network of compounding pharmacy relationships, has acquired intellectual property from Novel Drug Solutions and Eye Care Northwest, including a provisional patent application related to an ophthalmic compound for intraoperative ocular injection of anti-inflammatory and anti-bacterial agents. Imprimis believes this formulation could affect the $5 billion global cataract surgery drug market. The acquisition allows Imprimis to pursue the commercial development of certain proprietary innovations and also provides Imprimis with a preemptive right on additional intellectual property and drug development opportunities.

[Read More]

Imprimis acquires intellectual property for drug candidate

Friday, July 26, 2013

Imprimis Pharmaceuticals, which focuses on the commercialization of drug formulations utilizing the FDA drug development pathway, has acquired intellectual property for IPI-120, a novel drug formulation of both tranexamic acid, a synthetic derivative of the amino acid lysine, and an antibiotic. The company’s recently-filed patent application combines tranexamic acid with an antibiotic to provide the clotting effects along with protection or treatment against infection in a transdermal, local intra-wound application or intra-cavity instillation formulation.

[Read More]